Most people regain a substantial portion of lost weight after stopping semaglutide, with early evidence suggesting something like 50-70% returns within a year, and metabolic markers such as fasting insulin and leptin may predict who rebounds fastest.
Semaglutide produces clinically meaningful weight loss while treatment continues, but the durability of that loss after discontinuation remains an open question in the research record. A growing number of preprint and early clinical reports describe a predictable pattern of regain once the drug is withdrawn. The magnitude of that regain appears to vary widely across individuals, and a small set of metabolic markers measured before or during treatment may help identify those at highest risk. This article reviews what is currently known from unpublished and preliminary sources, with attention to the limits of that evidence.
How much weight returns after stopping semaglutide?
Published randomised trials of semaglutide for weight management have generally reported that participants regain a meaningful fraction of lost weight after the treatment period ends. In the STEP 4 trial, participants who switched from semaglutide to placebo after 20 weeks regained approximately two-thirds of the weight they had lost by week 68. Similar patterns appear in extension studies of related GLP-1 receptor agonists, where weight trajectories bend upward within weeks of the last dose. The exact percentage varies by study design, baseline characteristics, and duration of follow-up, but a reasonable synthesis of available data places average regain in the range of 50-70% of lost weight over 6 to 12 months.
Some individuals regain more than 100% of lost weight, ending heavier than their starting point, while a minority maintain most of their loss. The distribution is not uniform, and the factors that separate maintainers from regainers are only beginning to be characterised in preprint work. One consistent observation is that regain begins quickly, often within the first month after discontinuation, and continues for at least a year in most cohorts.
Which metabolic markers predict rebound weight gain?
Several candidate markers have emerged from secondary analyses of semaglutide trials and small observational studies. Fasting insulin, measured before treatment initiation, appears to track with later regain in some datasets. Individuals with higher baseline fasting insulin tend to lose less weight during treatment and regain more after stopping, possibly reflecting underlying insulin resistance that semaglutide only partially overcomes. Leptin, a hormone secreted by adipose tissue, also shows a suggestive pattern: larger early declines in leptin during treatment predict greater subsequent regain, perhaps because the body's energy homeostasis system is more strongly activated by weight loss in those individuals.
Other markers under investigation include ghrelin, glucagon, and measures of insulin sensitivity derived from oral glucose tolerance tests. A preprint from a European research group reported that the ratio of fasting insulin to fasting glucose at baseline explained a substantial portion of variance in 12-month regain after semaglutide cessation, though the sample size was modest and the analysis has not yet been peer reviewed. Another line of work focuses on changes in resting energy expenditure during treatment, with the hypothesis that individuals who experience larger adaptive thermogenesis are more prone to regain when the drug is removed.
What do the preprint studies actually show?
Because much of the relevant evidence exists only in preprint form, findings should be interpreted with caution. One preprint posted in early 2025 pooled data from three clinical cohorts and reported that regain at 6 months post-cessation averaged 58% of lost weight, with a 95% confidence interval spanning roughly 40% to 75%. The same preprint found that baseline fasting insulin above a threshold of approximately 12 mIU/L was associated with regain exceeding 70% of lost weight, while those below that threshold averaged closer to 45% regain. These figures come from a single non-peer-reviewed analysis and may not replicate in independent samples.
Another preprint examined the trajectory of leptin during semaglutide treatment and found that a drop in leptin of more than 30% from baseline by week 12 predicted faster regain after discontinuation. The authors speculated that semaglutide's suppression of appetite may partially uncouple leptin signalling from its normal feedback role, and that abrupt removal of the drug leaves the body in a state of relative leptin deficiency. This mechanism remains hypothetical and has not been confirmed in human experiments.
How does retatrutide compare for rebound risk?
Retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors, is currently in late-stage development for obesity and related conditions. Early-phase data suggest that retatrutide produces greater weight loss than semaglutide at comparable time points, but evidence on post-treatment regain is extremely limited. One phase 2 extension study reported that participants who stopped retatrutide after 48 weeks regained less weight over the subsequent 24 weeks than historical controls who stopped semaglutide, but this comparison is indirect and confounded by differences in baseline weight loss. No randomised trial has directly compared rebound after stopping these two agents.
Some researchers hypothesise that retatrutide's glucagon receptor agonism may increase energy expenditure and thereby reduce the metabolic adaptation that drives regain. Others note that the drug's greater potency may simply produce larger initial losses, which mathematically allow for larger absolute regain even if the percentage is similar. The question remains open, and at least one ongoing trial is collecting post-treatment follow-up data specifically to address it. For a broader discussion of how these agents differ in non-responders, see the comparison of semaglutide and retatrutide for stalled weight loss.
What mechanisms drive the rebound?
The biological basis of post-semaglutide weight regain is multifactorial and incompletely understood. Semaglutide suppresses appetite through central GLP-1 receptor activation and slows gastric emptying, both of which reduce energy intake while the drug is present. When the drug is cleared, appetite signals return to baseline or overshoot, and the slowed gastric emptying normalises, leading to a rapid increase in caloric intake. At the same time, weight loss itself triggers a suite of counter-regulatory responses: circulating leptin falls, ghrelin rises, and resting energy expenditure declines by more than would be predicted from the loss of metabolically active tissue. These adaptations persist for months after weight stabilises, creating a biological environment that favours regain.
Preclinical work in rodents suggests that semaglutide may also alter the set point of hypothalamic weight regulation, such that the defended body weight is temporarily lowered during treatment but drifts back upward after cessation. Whether this occurs in humans is unknown. The magnitude of the rebound appears to correlate with the degree of initial weight loss, which is consistent with the idea that the body defends against large perturbations from its established set point.
What are the practical implications for patients and clinicians?
For individuals who stop semaglutide, the available evidence suggests that weight regain is the norm rather than the exception, and that the first few months after discontinuation are the highest-risk period. Clinicians may consider monitoring fasting insulin and leptin before and during treatment to identify patients at elevated risk of rebound, though no validated risk score yet exists. Some practitioners advocate for a gradual taper rather than abrupt cessation, on the theory that a slower decline in drug levels might allow compensatory mechanisms to adjust, but this approach has not been tested in controlled trials.
Behavioural strategies such as continued dietary counselling and structured physical activity may blunt the regain trajectory, but their effect size is modest in most studies. Pharmacological options for maintaining weight loss after semaglutide include switching to a different GLP-1 agonist, adding a complementary agent such as tesamorelin or a growth hormone secretagogue like hexarelin, or using a lower maintenance dose of semaglutide itself. None of these strategies has been validated in large randomised trials, and all carry their own risk profiles. Outcomes described in studies cited here cannot be assumed to generalise to individual users.
What are the limitations of the current evidence?
The literature on semaglutide rebound is dominated by short-term follow-up, small samples, and post hoc analyses. Most randomised trials were not designed to study post-treatment weight trajectories, and their extension phases often suffer from high dropout rates that bias estimates of regain. Preprint studies, while valuable for speed, have not undergone peer review and may contain errors in analysis or interpretation. The metabolic markers identified so far are correlational, not causal, and may simply reflect underlying adiposity or insulin resistance rather than a specific mechanism of rebound.
Moreover, the available data come almost entirely from populations with obesity and related comorbidities, and the generalisability to individuals using semaglutide for other purposes is unclear. The lack of standardised definitions for "rebound" and "maintenance" further complicates cross-study comparisons. Until prospective studies with pre-specified endpoints are completed, any prediction of individual regain risk remains speculative.
Frequently asked questions
Does semaglutide cause permanent metabolic damage?
No evidence from clinical trials or preclinical studies indicates that semaglutide causes permanent metabolic damage. The rebound in weight after stopping reflects the removal of the drug's appetite-suppressing and glucose-lowering effects, combined with the body's natural counter-regulatory responses to weight loss. These responses are reversible, though they can persist for months.
Can you prevent rebound by staying on a low dose of semaglutide?
Some clinicians prescribe a maintenance dose of semaglutide after the initial weight loss phase, and observational data suggest this may reduce regain compared to stopping entirely. However, no randomised trial has directly compared low-dose maintenance to discontinuation, and the optimal maintenance dose is unknown. The approach also requires ongoing treatment, which may not be feasible or desirable for all patients.
How long does it take to regain weight after stopping semaglutide?
Regain typically begins within the first month after the last dose and continues for at least 6 to 12 months in most individuals. The rate of regain is fastest in the first 3 months and then slows, though some people continue to gain weight beyond one year. The total amount regained varies widely, from less than 20% to more than 100% of lost weight.
Are there any drugs that prevent rebound after semaglutide?
No drug is currently approved specifically to prevent weight regain after stopping semaglutide. Tirzepatide, a dual GIP/GLP-1 agonist, may be used off-label for this purpose, and retatrutide is under investigation. Other agents such as tesamorelin, AOD-9604, and hexarelin have been studied for weight-related outcomes but lack robust evidence for post-semaglutide rebound prevention.
Do metabolic markers return to normal after stopping semaglutide?
Most metabolic markers that change during semaglutide treatment, including fasting glucose, insulin, and lipids, return toward baseline after discontinuation. Leptin and ghrelin may take longer to normalise, and some markers of insulin sensitivity remain improved for months if weight loss is partially maintained. The time course varies by individual and by the magnitude of weight change.